NVIDIA & Singular Genomics Team Up to Boost Next-Gen Sequencing Capabilities

Singular Genomics Systems and NVIDIA are teaming up to validate and optimize the G4 Sequencing Platform with NVIDIA Clara Parabricks for accelerated bioinformatics applications. 

The G4 sequencer is Singular Genomics’ first benchtop sequencing platform, utilizing its exclusive ​​4-color sequencing by synthesis (SBS) chemistry and equipped with NVIDIA RTX A6000 for AI-enabled basecalling. This collaboration will enable Clara Parabricks access for the Singular’s G4 sequencing system, enabling accelerated bioinformatics applications in whole-genome, cancer, RNA sequencing, and targeted gene screening, coupled with Amazon Cloud functionalities.

As demand for sequencing increases, the volume of data generated grows exponentially, algorithms and workflows used for data analysis are known to be the primary bottleneck. NVIDIA’s Clara Parabricks addresses this issue with an accelerated and scalable suite optimized for genomic analysis on graphics processing units (GPUs). This collaboration further extends NVIDIA’s technology to downstream genomics workflow. 

“Time to results is crucial across most NGS applications, and we believe that Clara Parabricks and NVIDIA’s best-in-class GPU architecture combined with the speed and flexibility of the G4 Sequencing Platform is a natural fit,” said George Vacek, NVIDIA Global Director of Genomics Alliances.

Related article: Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

Singular Genomics’ First Commercial Sequencing Platform

Aiming to compete with Illumina in the benchtop sequencer market, the San Diego-based company went public in May 2021 and launched its first commercial sequencer later that year. Singular Genomics has deals to make sample library preparation kits from Twist Bioscience, New England BioLabs, and Dovetail compatible with its platform, integrating established workflows into the G4.

Wasting no time to support its first product, the company later secured a partnership with Broad Institute to integrate the Terra platform developed jointly with Microsoft and Alphabet into G4, further ameliorating its cloud data analysis abilities.

The G4x4, a four-instrument configuration designed to address customers with high sequencing output demands, is scheduled for launch before the end of 2022. The company did not disclose any financial and other terms of the NVIDIA agreement.

Related posts:

Takeda Walks Away From Microbiome Deal With Finch BioAro and GeneOnline Forge Partnership to Revolutionize Genetic Analysis in Asia Pacific Market Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul

Author

Fujie Tham